Spire Healthcare Group (LON:SPI) Stock Price Down 18.1% After Analyst Downgrade

Spire Healthcare Group plc (LON:SPI)’s stock price traded down 18.1% during mid-day trading on Friday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 183.95 ($2.37). 8,024,729 shares changed hands during mid-day trading, an increase of 1,005% from the average session volume of 726,218 shares. The stock had previously closed at GBX 224.50 ($2.89).

Spire Healthcare Group Trading Down 4.9 %

The stock has a market cap of £720.08 million, a P/E ratio of 25.52, a P/E/G ratio of 1.06 and a beta of 0.96. The company has a current ratio of 0.70, a quick ratio of 0.74 and a debt-to-equity ratio of 62.25. The company has a 50-day moving average price of GBX 228.24 and a two-hundred day moving average price of GBX 230.26.

Spire Healthcare Group (LON:SPI) last released its earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. On average, research analysts expect that Spire Healthcare Group plc will post 15.6634747 EPS for the current fiscal year.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.